Genaera

Genaera Corporation is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. Our research and development efforts are focused on anti-angiogenesis, obesity, infectious and respiratory diseases. We were incorporated in the State of Delaware in 1987 as Magainin Pharmaceuticals, Inc. and began operations in 1988. We changed our name to Genaera Corporation on March 9, 2001. Genaera maintains its headquarters and laboratory facilities in Plymouth Meeting, Pennsylvania.

Contact Details: 5110 Campus Drive Plymouth Meeting PA 19462 United States of America Tel: (610) 941-4020 Fax: (610) 941-5399 Email: info@genaera.com WWW: www.genaera.com/

Loading...

Recent Publications by Genaera:
Assessment of renal injury in vivo. The ICH S7A (Safety Pharmacology for Human Pharmaceuticals) guidelines...	13th December, 2005	Genaera Corporation, 5110 Campus Drive, Plymouth Meeting, PA 19462, USA.	J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):30-45. DOI Direct Link
Quantitative analysis of squalamine, a self-ionization-suppressing aminosterol sulfate, in human plasma by LC-MS/MS. The special physico-chemical property of squalamine enables the formation...	7th October, 2004	Genaera Corporation, 5/10 Campus Drive, Plymouth Meeting, PA 19462, USA.	J Pharm Biomed Anal. 2004 Feb 18;34(3):631-41.
Determination of degradation products of squalamine lactate using LC/MS. Heat, acid and base stress methods were applied to study the stability of...	6th January, 2004	Genaera Corporation, 5110 Campus Drive, Plymouth Meeting, PA 19462, USA.	J Pharm Biomed Anal. 2003 Apr 24;32(1):85-96.
A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction. We have previously shown that expression of a Ca2+-activated Cl- channel...	29th May, 2003	Genaera Corporation, 5110 Campus Drive, Plymouth Meeting, PA 19462, USA.	Novartis Found Symp. 2002;248:150-65; discussion 165-70, 277-82.

Press Releases on Genaera:
DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller	7th July, 2009	DOR BioPharma, Inc.	PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it recently
Genaera Corporation Board of Directors Dissolves Corporation and Forms Liquidating Trust	12th June, 2009	Genaera Corporation	PLYMOUTH MEETING, Pa., June 12 /PRNewswire-FirstCall/ -- Genaera Corporation ("the Company") (Nasdaq: GENR) today announced that the Company's Board of Directors voted to dissolve the
Genaera Corporation Announces Results of Special Meeting of Stockholders	5th June, 2009	Genaera Corporation	PLYMOUTH MEETING, Pa., June 5 /PRNewswire-FirstCall/ -- Genaera Corporation ("the Company") (Nasdaq: GENR) today announced that proxies representing a majority of the shares voted at the
Genaera Receives Non-Compliance Notice from Nasdaq	27th May, 2009	Genaera Corporation	PLYMOUTH MEETING, Pa., May 27 /PRNewswire-FirstCall/ -- Genaera Corporation ("the Company") (Nasdaq: GENR) today announced that it has received notification from Nasdaq stating that Genaera
Genaera Corporation Announces Approval of Plan of Liquidation and Dissolution by Board of Directors	28th April, 2009	Genaera Corporation	PLYMOUTH MEETING, Pa., April 28 /PRNewswire-FirstCall/ -- Genaera Corporation (the "Company")(Nasdaq: GENR) today announced that its Board of Directors has determined, after extensive and

BioNews Results for Genaera:
Ohr Pharmaceutical (OTCBB: OHRP) CEO Announces Completion of Biotech Transformation With Acquisition of Phase	NewsBlaze:  Nov 11 2009 12:53AM Matching: genaera
Ohr Pharmaceutical (OTCBB: OHRP) CEO Announces Completion of Biotech Transformation With Acquisition of Phase	Pharmacy Choice:  Nov 10 2009 9:29PM Matching: genaera
Ohr Pharmaceutical (OTCBB: OHRP) CEO Announces Completion of Biotech Transformation With Acquisition of Phase	Marketwire via Yahoo!:  Nov 10 2009 2:38PM Matching: genaera
Ohr Pharmaceutical (OTCBB: OHRP) CEO Announces Completion of Biotech Transformation With Acquisition of Phase	Yahoo! Canada:  Nov 10 2009 2:14PM Matching: genaera
Arena Pharmaceuticals Reports Positive BLOSSOM Trial Results	Pharmaceutical Business Review:  Sep 21 2009 11:46PM Matching: genaera
Promote your company here: BioNewsCast - Press Release Distribution	→View more Genaera news.

Genaera Clinical Trials:
A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers

Genaera Patents:
US Patent No.	Title
7504409	Mucin synthesis inhibitors
6388108	Aminosterol compounds and uses thereof
6576434	Methods for identification of agents which modulate chloride channel activity
6596712	Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
6602850	Method of treating asthma using soluble IL-9 receptor variants
→View more Genaera patents.

Genaera (GENR) Financial information Links from Barchart
GENR Quote from from Barchart.com
GENR Chart from from Barchart.com
GENR Profile from from Barchart.com
GENR Opinion from from Barchart.com
→View more Genaera finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 535 times since April 2007, the link to the organisation's website has been followed 69 times

Recent Search Terms used to find this page: genara | genaera fax | Magainin Pharmaceuticals Inc genaera | patent genaera MSI | infectious disease genaera | .

Search for more companies in Plymouth Meeting

Search for more companies in PA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Genaera